infectious diseases
Respiratory Virus Research Services
Preclinical Respiratory Virus Research Services
At BIOQUAL, we have decades of experience delivering in vitro and in vivo preclinical respiratory virus research studies for high-priority human pathogens, including coronaviruses (SARS-CoV-1, SARS-CoV-2), influenza, and respiratory syncytial virus (RSV).
We offer a wide range of relevant animal models and in vitro assays to support the development of novel vaccines and therapeutics for respiratory viruses, as well as custom model and assay development. Our highly experienced team and secure containment facilities up to Biosafety Level 3 (BSL-3) provide the highest safety standards for working with high-risk wild-type viruses, and can rapidly adapt to meet emerging global health threats.
Respiratory Virus Research Capabilities
BIOQUAL offers a full range of in vivo and in vitro preclinical research services up to BSL-3 to support the development of novel vaccines and therapeutics for respiratory viruses, as well as strain testing. Our services include:
In Vivo Respiratory Virus Models
We offer a wide range of relevant respiratory virus models including mouse, ferret, and non-human primates (NHPs) to enable in-depth study of infection mechanisms, immune responses, and therapeutic efficacy. Whatever the pathogen, our team draws on decades of hands-on experience to help you choose the right model for your research question or develop a new one if none exists.
In Vitro Respiratory Virus Assays
We provide extensive laboratory services including in vitro viral load and neutralization assays, respiratory virus stock generation, influenza strain testing, and characterization of immune responses to respiratory infections. We use our proven methodologies and scientific expertise to optimize existing assays and develop customized procedures, delivering accurate, consistent results that support robust decision making along the preclinical journey.
Integrated Preclinical Research Capabilities
By integrating in vitro laboratory services with small and large animal models, BIOQUAL supports preclinical research at every stage from the lab to the clinic, driving efficiency and ensuring regulatory compliance. Our clients benefit from expert advice, consistent methodologies, and high quality standards to advance therapeutic and vaccine candidates confidently toward clinical development.
Respiratory Virus Models
We offer a wide range of relevant respiratory virus animal models for influenza, RSV and coronaviruses, as well as custom model development.
Influenza Animal Models
- BALB/c mice
- Ferrets
- Cynomolgus macaques
- Rhesus macaques
SARS-CoV-1/SARS-CoV-2 Animal Models
- hACE2 Tg transgenic mice
- hTMPRSS2 KI knock-in mice
- Golden Syrian hamsters
- Rhesus macaques
- Cynomolgus macaques
- African green monkeys
- Marmosets
RSV Animal Models
- BALB/c mice
- Cynomolgus macaques
- African green monkeys
Respiratory Virus Assays
We offer a wide range of in vitro assays aimed at understanding viral- or vaccine-induced immune responses for respiratory viruses including influenza, RSV, and coronaviruses (SARS-CoV-1, SARS-CoV-2).
Our facilities are equipped with containment up to BSL-3 to receive and process samples infected with respiratory viruses safely and securely. Our standard preclinical assay services range from ELISA assays to detailed immune cell characterization, as well as hemagglutination assays (HA) hemagglutination inhibition assays (HAI), neuraminidase inhibition assays (NAI), microneutralization (MN) and enzyme-linked lectin assays (ELLA) assays for influenza. We are also happy to work with our clients to develop custom assays to support the development of novel vaccines and antivirals.
Viral Load Testing
We offer qRT-PCR, TCID50, and plaque assays for respiratory viral titer and viral load testing.
Immunogenicity Assays
We provide a wide range of immunogenicity assays relevant to respiratory viruses including binding antibody ELISA assays, HA, HAI, ELLA, MN, NAI, and neutralization assay services.
Immune Response Characterization
We offer flow cytometry characterization and functional assays of immune cell populations in response to respiratory virus infection or vaccination, as well as cytokine/chemokine detection and analysis using ELISpot, Luminex, and ELISA.
Respiratory Virus Stock Generation
We generate high-quality, well-characterized stocks of respiratory viruses in cells, as well as influenza virus stocks in embryonated chicken eggs.
Influenza Strain Testing Services
We can test for a wide variety of influenza A and B virus strains, including seasonal flu virus strains to inform annual vaccine development.
Antiviral Assays
We develop and deliver assays to support the preclinical development of novel antiviral drugs for respiratory viruses, such as microneutralization assays for antibody-based therapeutics (MN assay), plaque assays, and CPE/TCID50 assays for small molecules.
Integrated Preclinical Research Capabilities
At BIOQUAL, we know that innovative science needs solid support at every step of the journey from the lab to the clinic. Our preclinical research services range from early-stage in vitro assays and screening through to critical in vivo studies in a wide range of animal models, ensuring our partners have the robust, reliable data they need to advance groundbreaking vaccine and therapeutic research programs.
Don’t see the model or assay you need? Talk to our scientists about our custom solutions.
Why Work With BIOQUAL
With more than four decades of experience, BIOQUAL is the expert preclinical CRO specializing in infectious disease and immunology. We are trusted by hundreds of clients across government, biopharma, and academic research institutes to deliver the quality, safety, and flexibility that they demand.
Our highly experienced team and state-of-the-art Biosafety Level 3 facilities provide the highest safety standards for working with high-risk wild-type pathogens. And our AAALAC accreditation demonstrates our dedication to humane and compliant animal care, prioritizing welfare and establishing a reliable foundation for producing high-quality research data.
Every preclinical research program comes with its own timeline, budget, and scientific challenges, so we work closely with our clients to develop tailored approaches that meet the specific needs of each study. We have the flexibility to adapt to changing demands and shifting priorities, and a proven track record of moving fast in response to rapidly emerging public health threats.
Respiratory Virus Research Publications
Testing COVID-19 Vaccines
We evaluated Moderna’s mRNA-1273 (Spikevax®) COVID-19 vaccine in NHPs
Rapid COVID-19 Model Development
We quickly developed an NHP model for SARS-CoV-2 infection at the start of the COVID-19 pandemic.
Developing a ‘Universal’ Flu Vaccine
We supported preclinical development of a novel quadrivalent influenza vaccine made from nanoparticles.


